Literature DB >> 29907535

Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.

Shang-Yi Lin1, Yi-Wen Chiu2, Po-Liang Lu3, Shang-Jyh Hwang2, Tun-Chieh Chen4, Min-Han Hsieh5, Yen-Hsu Chen6.   

Abstract

The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before. This is the first study to evaluate the safety and tolerability of 3HP in this population and revealed a completion rate of 65.4%. The therapy was not associated with hepatotoxicity, but with high rates of adverse events (69.2%).
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  3HP; Hemodialysis; LTBI; Latent tuberculosis; Rifapentine

Mesh：

Substances：

Year:  2018        PMID： 29907535     DOI： 10.1016/j.jmii.2018.05.003

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


  7 in total

1.  Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study.

Authors:  Shu-Yung Lin; Jia-Yih Feng; Chih-Yuan Lee; Yi-Chih Lin; Yu-Hsiang Chou; Kuan-Yin Lin; Yu-Feng Wei; Shu-Wen Lin; Chin-Hao Chang; Ping-Huai Wang; Chin-Chung Shu; Jann-Yuan Wang; Chong-Jen Yu
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review.

Authors:  Noor Ul Ain Shahid; Noreen Naguit; Rakesh Jakkoju; Sadia Laeeq; Tiba Reghefaoui; Hafsa Zahoor; Ji Hyun Yook; Muneeba Rizwan; Lubna Mohammed
Journal:  Cureus       Date:  2022-05-17

Review 3.  Update of the mechanism and characteristics of tuberculosis in chronic kidney disease : Review article.

Authors:  Xuehan Zhang; Pingshan Chen; Gaosi Xu
Journal:  Wien Klin Wochenschr       Date:  2022-03-07       Impact factor: 2.275

4.  Comparison of three short-course rifamycin-based regimens for the prevention of tuberculosis in patients with end-stage kidney disease: Study protocol for a randomised clinical trial (RIFAKiD-TB trial).

Authors:  Miguel Santin; Sandra Perez-Recio; Maria D Grijota; Luis Anibarro; Jose M Barcala; Maria L De Souza-Galvao; Paloma Gijon; Rafael Luque; Francesca Sanchez
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

5.  Patient and health care system characteristics are associated with delayed treatment of tuberculosis cases in Taiwan.

Authors:  Chien-Chou Chen; Po-Huang Chiang; Yen-Hsu Chen; I-Chun Fan; Ta-Chien Chan
Journal:  BMC Health Serv Res       Date:  2019-11-19       Impact factor: 2.655

Review 6.  Immunometabolism of Immune Cells in Mucosal Environment Drives Effector Responses against Mycobacterium tuberculosis.

Authors:  Mohd Hatimi Tukiman; Mohd Nor Norazmi
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

7.  Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study.

Authors:  Hung-Ling Huang; Wei-Chang Huang; Kun-Der Lin; Shin-Shin Liu; Meng-Rui Lee; Meng-Hsuan Cheng; Chun-Shih Chin; Po-Liang Lu; Chau-Chyun Sheu; Jann-Yuan Wang; I-Te Lee; Inn-Wen Chong
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.